IPSEN (OTCMKTS:IPSEY) Shares Gap Up – Should You Buy?

IPSEN (OTCMKTS:IPSEY) gapped up before the market opened on Wednesday . The stock had previously closed at $44.07, but opened at $47.11. IPSEN shares last traded at $47.11, with a volume of 2,108 shares traded.

Wall Street Analyst Weigh In

A number of analysts recently commented on IPSEY shares. Zacks Research upgraded IPSEN to a “hold” rating in a research report on Friday, May 29th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Finally, HC Wainwright restated a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, IPSEN currently has an average rating of “Hold”.

IPSEN Stock Performance

The business has a 50 day moving average of $46.35 and a 200 day moving average of $45.00.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).